Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $391 | $625 | $820 | $1,083 | $1,697 |
| Gross Profit | -$216 | -$468 | -$541 | -$446 | -$222 |
| Operating Income | -$216 | -$468 | -$541 | -$446 | -$222 |
| Net Income | -$230 | -$472 | -$548 | -$435 | -$190 |
Over the five-year period, Natera, Inc. experienced robust revenue growth—from USD 391 million in 2020 to nearly USD 1.70 billion in 2024. This represents a compounded increase that indicates strong market demand and significant scaling of its operations, despite the overall negative bottom line. Revenue growth was particularly notable in the later years, with an approximately 56.7% jump from 2023 to 2024. However, the gross profit, operating income, and net income metrics have remained in negative territory throughout this period. Notably, the losses in gross profit narrowed considerably from a low of about -USD 541 million in 2022 to -USD 222 million in 2024, suggesting some improvements in managing cost structures or achieving economies of scale. The year-over-year improvements in operating income and net income, which similarly moved from more negative losses toward smaller deficits, indicate that while the company is still operating at a net loss, efforts to curb expenses or improve operational efficiency may be gradually paying off. The significant volatility—exemplified by changes exceeding 20% in revenue and cost line items—warrants close attention. Given Natera’s role in the genetic testing and diagnostics industry, characterized by heavy R&D investment and a long ramp-up period towards profitability, the large increases in revenue might reflect market acceptance of innovative testing solutions. Overall, while the trends point to positive developments in reducing losses and scaling revenues, sustaining improved operational margins will be crucial for the company’s long-term financial health and sustainability.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.